An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches

Review expert insights on the latest developments in managing myelodysplastic syndromes with a focused commentary downloadable slides podcast and on-demand webcast from a live CCO symposium at ASH 2022.

Share

Program Content

No activities added yet

Activities

Managing Lower-risk MDS
Strategies for Managing Very Low-Risk, Low-Risk and Intermediate-Risk MDS
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2022

Expires: December 08, 2023

TX for Higher Risk MDS
Emerging Therapies in the Treatment of Patients With Higher Risk MDS in Frontline and Post-HMA Failure Settings
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2022

Expires: December 08, 2023

MDS Classification and Risk
Myelodysplastic Syndromes: Diagnosis, Classification, and Risk Stratification
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2022

Expires: December 08, 2023

EP: MDS Personalized Management
Express Points An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 21, 2022

Expires: December 20, 2023

Activities

MDS Tx Challenges
Challenges in Personalizing the Management of Myelodysplastic Syndromes: Case Studies
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 16, 2022

Expires: November 15, 2023

Faculty

cover img faculity

María Díez Campelo, MD, PhD

Associate Professor
Department of Medicine
School of Medicine
University of Salamanca
Hematologist
Department of Hematology
University Hospital of Salamanca
Salamanca, Spain

cover img faculity

Rami Komrokji, MD

Section Head – Leukemia & MDS, Vice Chair
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

cover img faculity

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bristol Myers Squibb

Geron

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Learning Objectives

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
  • Formulate strategies for integrating TRK and RET inhibitors into practice that include patient discussions, adverse event monitoring and management, and methods to enroll qualified patients on clinical trials
  • Develop treatment strategies for patients with cancer who develop acquired resistance to first-generation TRK and RET inhibitor therapy

  • Manage treatment-related symptoms associated with the treatment of RET-altered or
    NTRK fusion–positive cancer

  • Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials